

Review of: "[Viewpoint] Vaccination campaigns against Covid-19 may promote vaccine hesitancy toward mostly well-established, safe, and effective vaccines"

Salma Elmukashfi Eltahir Mohammed¹

¹ Uppsala University

Potential competing interests: No potential competing interests to declare.

I find the article by Eduardo Missoni and Kasturi Sen to be a significant contribution to the ongoing debate about vaccine Covid-19 hesitancy and trust, particularly in the domains of clinical trials and safety surveillance for Covid-19 vaccines. The focus on these elements is both timely and essential given the prevailing vaccine hesitancy in several sectors of society.

Strengths:

The issue of transparency is clearly articulated, particularly highlighting the absence of publicly accessible raw data and the absence of open scientific debate. These elements are pinpointed as core contributors to prevailing public scepticism.

The discussion around safety surveillance, notably post-marketing assessments, aligns well with current concerns about vaccine safety, making this article highly relevant.

The article is well-referenced, providing a solid basis for the points raised.

Areas for Improvement:

The article would gain further credibility by discussing the ongoing safety surveillance mechanisms that are in place post-marketing, such as adverse event reporting systems and long-term studies.

The authors call for raw data to be released but do not specify how this might practically be implemented while preserving patient confidentiality and proprietary information. Adding this could strengthen their argument.